We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Judge Compels Glaxo CEO To Answer Questions In Challenge To AZT Patent

Law360 (April 4, 2005, 12:00 AM EDT) -- A California federal court has ruled that GlaxoSmithKline's chief executive officer must answer further questions in a deposition in a challenge to its patent rights to AZT (Retrovir), the first AIDS drug.

As part of the legal proceedings, attorneys for plaintiff AIDS Healthcare Foundation (AHF) deposed Glaxo CEO Jean-Pierre Garnier in late January 2005 in Philadelphia. AHF said Garnier left questions unanswered during that deposition, prompting its attorneys to petition the court to be able to continue Garnier's deposition.

In late March, U.S. Court Magistrate Judge...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.